Cargando…

Efficacy of a Novel Bi-Steric mTORC1 Inhibitor in Models of B-Cell Acute Lymphoblastic Leukemia

The mechanistic target of rapamycin (mTOR) is a kinase whose activity is elevated in hematological malignancies. mTOR-complex-1 (mTORC1) phosphorylates numerous substrates to promote cell proliferation and survival. Eukaryotic initiation factor 4E (eIF4E)-binding proteins (4E-BPs) are mTORC1 substra...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Bianca J., Mallya, Sharmila, Dinglasan, Nuntana, Fung, Amos, Nguyen, Tram, Herzog, Lee-or, Thao, Joshua, Lorenzana, Edward G., Wildes, David, Singh, Mallika, Smith, Jacqueline A. M., Fruman, David A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366290/
https://www.ncbi.nlm.nih.gov/pubmed/34408976
http://dx.doi.org/10.3389/fonc.2021.673213
_version_ 1783738872826429440
author Lee, Bianca J.
Mallya, Sharmila
Dinglasan, Nuntana
Fung, Amos
Nguyen, Tram
Herzog, Lee-or
Thao, Joshua
Lorenzana, Edward G.
Wildes, David
Singh, Mallika
Smith, Jacqueline A. M.
Fruman, David A.
author_facet Lee, Bianca J.
Mallya, Sharmila
Dinglasan, Nuntana
Fung, Amos
Nguyen, Tram
Herzog, Lee-or
Thao, Joshua
Lorenzana, Edward G.
Wildes, David
Singh, Mallika
Smith, Jacqueline A. M.
Fruman, David A.
author_sort Lee, Bianca J.
collection PubMed
description The mechanistic target of rapamycin (mTOR) is a kinase whose activity is elevated in hematological malignancies. mTOR-complex-1 (mTORC1) phosphorylates numerous substrates to promote cell proliferation and survival. Eukaryotic initiation factor 4E (eIF4E)-binding proteins (4E-BPs) are mTORC1 substrates with an integral role in oncogenic protein translation. Current pharmacological approaches to inhibit mTORC1 activity and 4E-BP phosphorylation have drawbacks. Recently we described a series of bi-steric compounds that are potent and selective inhibitors of mTORC1, inhibiting 4E-BP phosphorylation at lower concentrations than mTOR kinase inhibitors (TOR-KIs). Here we report the activity of the mTORC1-selective bi-steric inhibitor, RMC-4627, in BCR-ABL-driven models of B-cell acute lymphoblastic leukemia (B-ALL). RMC-4627 exhibited potent and selective inhibition of 4E-BP1 phosphorylation in B-ALL cell lines without inhibiting mTOR-complex-2 (mTORC2) activity. RMC-4627 suppressed cell cycle progression, reduced survival, and enhanced dasatinib cytotoxicity. Compared to a TOR-KI compound, RMC-4627 was more potent, and its effects on cell viability were sustained after washout in vitro. Notably, a once-weekly, well tolerated dose reduced leukemic burden in a B-ALL xenograft model and enhanced the activity of dasatinib. These preclinical studies suggest that intermittent dosing of a bi-steric mTORC1-selective inhibitor has therapeutic potential as a component of leukemia regimens, and further study is warranted.
format Online
Article
Text
id pubmed-8366290
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-83662902021-08-17 Efficacy of a Novel Bi-Steric mTORC1 Inhibitor in Models of B-Cell Acute Lymphoblastic Leukemia Lee, Bianca J. Mallya, Sharmila Dinglasan, Nuntana Fung, Amos Nguyen, Tram Herzog, Lee-or Thao, Joshua Lorenzana, Edward G. Wildes, David Singh, Mallika Smith, Jacqueline A. M. Fruman, David A. Front Oncol Oncology The mechanistic target of rapamycin (mTOR) is a kinase whose activity is elevated in hematological malignancies. mTOR-complex-1 (mTORC1) phosphorylates numerous substrates to promote cell proliferation and survival. Eukaryotic initiation factor 4E (eIF4E)-binding proteins (4E-BPs) are mTORC1 substrates with an integral role in oncogenic protein translation. Current pharmacological approaches to inhibit mTORC1 activity and 4E-BP phosphorylation have drawbacks. Recently we described a series of bi-steric compounds that are potent and selective inhibitors of mTORC1, inhibiting 4E-BP phosphorylation at lower concentrations than mTOR kinase inhibitors (TOR-KIs). Here we report the activity of the mTORC1-selective bi-steric inhibitor, RMC-4627, in BCR-ABL-driven models of B-cell acute lymphoblastic leukemia (B-ALL). RMC-4627 exhibited potent and selective inhibition of 4E-BP1 phosphorylation in B-ALL cell lines without inhibiting mTOR-complex-2 (mTORC2) activity. RMC-4627 suppressed cell cycle progression, reduced survival, and enhanced dasatinib cytotoxicity. Compared to a TOR-KI compound, RMC-4627 was more potent, and its effects on cell viability were sustained after washout in vitro. Notably, a once-weekly, well tolerated dose reduced leukemic burden in a B-ALL xenograft model and enhanced the activity of dasatinib. These preclinical studies suggest that intermittent dosing of a bi-steric mTORC1-selective inhibitor has therapeutic potential as a component of leukemia regimens, and further study is warranted. Frontiers Media S.A. 2021-08-02 /pmc/articles/PMC8366290/ /pubmed/34408976 http://dx.doi.org/10.3389/fonc.2021.673213 Text en Copyright © 2021 Lee, Mallya, Dinglasan, Fung, Nguyen, Herzog, Thao, Lorenzana, Wildes, Singh, Smith and Fruman https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Lee, Bianca J.
Mallya, Sharmila
Dinglasan, Nuntana
Fung, Amos
Nguyen, Tram
Herzog, Lee-or
Thao, Joshua
Lorenzana, Edward G.
Wildes, David
Singh, Mallika
Smith, Jacqueline A. M.
Fruman, David A.
Efficacy of a Novel Bi-Steric mTORC1 Inhibitor in Models of B-Cell Acute Lymphoblastic Leukemia
title Efficacy of a Novel Bi-Steric mTORC1 Inhibitor in Models of B-Cell Acute Lymphoblastic Leukemia
title_full Efficacy of a Novel Bi-Steric mTORC1 Inhibitor in Models of B-Cell Acute Lymphoblastic Leukemia
title_fullStr Efficacy of a Novel Bi-Steric mTORC1 Inhibitor in Models of B-Cell Acute Lymphoblastic Leukemia
title_full_unstemmed Efficacy of a Novel Bi-Steric mTORC1 Inhibitor in Models of B-Cell Acute Lymphoblastic Leukemia
title_short Efficacy of a Novel Bi-Steric mTORC1 Inhibitor in Models of B-Cell Acute Lymphoblastic Leukemia
title_sort efficacy of a novel bi-steric mtorc1 inhibitor in models of b-cell acute lymphoblastic leukemia
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366290/
https://www.ncbi.nlm.nih.gov/pubmed/34408976
http://dx.doi.org/10.3389/fonc.2021.673213
work_keys_str_mv AT leebiancaj efficacyofanovelbistericmtorc1inhibitorinmodelsofbcellacutelymphoblasticleukemia
AT mallyasharmila efficacyofanovelbistericmtorc1inhibitorinmodelsofbcellacutelymphoblasticleukemia
AT dinglasannuntana efficacyofanovelbistericmtorc1inhibitorinmodelsofbcellacutelymphoblasticleukemia
AT fungamos efficacyofanovelbistericmtorc1inhibitorinmodelsofbcellacutelymphoblasticleukemia
AT nguyentram efficacyofanovelbistericmtorc1inhibitorinmodelsofbcellacutelymphoblasticleukemia
AT herzogleeor efficacyofanovelbistericmtorc1inhibitorinmodelsofbcellacutelymphoblasticleukemia
AT thaojoshua efficacyofanovelbistericmtorc1inhibitorinmodelsofbcellacutelymphoblasticleukemia
AT lorenzanaedwardg efficacyofanovelbistericmtorc1inhibitorinmodelsofbcellacutelymphoblasticleukemia
AT wildesdavid efficacyofanovelbistericmtorc1inhibitorinmodelsofbcellacutelymphoblasticleukemia
AT singhmallika efficacyofanovelbistericmtorc1inhibitorinmodelsofbcellacutelymphoblasticleukemia
AT smithjacquelineam efficacyofanovelbistericmtorc1inhibitorinmodelsofbcellacutelymphoblasticleukemia
AT frumandavida efficacyofanovelbistericmtorc1inhibitorinmodelsofbcellacutelymphoblasticleukemia